BRISBANE, Calif., Jan. 17 /PRNewswire/ -- Pharmix Corporation, a company pioneering a comprehensive approach to multi-objective drug engineering, today announced that Jack M. Anthony has been named the company’s President and Chief Executive Officer.
“Jack’s extensive experience at both large and small companies and his proven track record of establishing and growing companies alongside large pharmaceutical partners will be critical as Pharmix rolls out its proprietary drug engineering process, which combines unprecedented predictive power with the ability to design compounds against the multiple objectives that define a future market-leading agent,” stated Lucio Lanza, Chairman of Pharmix Corporation. “Pharmix is truly leveraging the convergence of Silicon Valley technologies and pharmaceutical industry know-how to efficiently engineer novel, successful therapeutics with reduced risk and optimized profiles. The time is ripe for Jack and his team to broadly apply the power of Pharmix’s capabilities to building its own pipeline as well as for current and future partners.”
Pharmix is focused on producing novel pharmaceuticals with optimized characteristics, including specific, desirable attributes. The company has developed a breakthrough, comprehensive drug engineering process, which combines advances in computer science, molecular modeling and bioinformatics to produce a fundamentally new way of designing pharmaceuticals with increased probability of success.
“I am very pleased to be joining Pharmix, a company with an outstanding team of scientists and engineers armed with a unique approach to drug design and development, as well as its own pipeline of novel active compounds produced using the company’s proprietary technologies,” stated Mr. Anthony. “Pharmix’s objective is to reduce risks in the preclinical and clinical process, potentially minimizing large capital investments in linear drug discovery, and, more importantly, reducing the time it takes to get a drug from the laboratory to the patient. As we move forward, we aim to further enhance our drug engineering capabilities, attract additional early adopters and demonstrate that our deliverables to clients are engineered drugs with predicted, optimized and validated characteristics. I am delighted to be part of this exciting business opportunity.”
Mr. Anthony brings more than 30 years of experience in pharmaceutical and biotechnology product management and business development. Prior to joining Pharmix, Mr. Anthony, age 59, was most recently Senior Vice President of Business Development at Saegis Pharmaceuticals where he was responsible for its CNS corporate development and licensing activities. Previously, Mr. Anthony was Senior Vice President of Business and Commercial Development at Tularik, where he oversaw the company’s business development initiatives. Prior to Tularik, Mr. Anthony held senior-level business development and marketing positions at FibroGen at Cell Therapeutics and Inhale Therapeutics (now Nektar) completing a number of research, development and commercialization agreements with global pharmaceutical and life sciences companies. Previously, Mr. Anthony served as Vice President of Business Development at Applied Immune Sciences (now part of Sanofi-Aventis). He was also General Manager of its chain of Cell Therapy Centers, ExVit. Mr. Anthony began his career at Baxter Healthcare where he held positions of increasing responsibility over 14 years including a Vice President in Baxter’s Blood Therapy Group.
About Pharmix Corporation
Pharmix Corporation approaches small molecule drug engineering as a challenge in multi-parameter optimization. Pharmix’s process enables the company to make quantitative predictions of unprecedented accuracy, scale and scope and to design novel compounds that avoid many issues that impact candidate attrition, resulting in an improved probability of success in the laboratory, in the clinic and in the marketplace. Pharmix is working with pharmaceutical and biotechnology companies in a variety of distinct projects to enhance their pipeline robustness, as well as moving its own compounds of interest forward towards human clinical trials. For more information, please visit www.pharmix.com.
Source: Pharmix Corporation
